Oxford Biomedica plc (LON: OXB)
London
· Delayed Price · Currency is GBP · Price in GBX425.00
-1.50 (-0.35%)
Dec 23, 2024, 4:35 PM BST
Oxford Biomedica Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 97.28 | 89.54 | 139.99 | 142.8 | 87.73 | 64.06 | Upgrade
|
| Revenue Growth (YoY) | -18.26% | -36.04% | -1.97% | 62.77% | 36.95% | -4.07% | Upgrade
|
| Cost of Revenue | 61.54 | 49.81 | 70.81 | 60.16 | 41.66 | 35.72 | Upgrade
|
| Gross Profit | 35.74 | 39.73 | 69.18 | 82.64 | 46.07 | 28.34 | Upgrade
|
| Selling, General & Admin | 25.15 | 25.41 | 23.12 | 13.95 | 11.26 | 11.88 | Upgrade
|
| Research & Development | 80.73 | 103.1 | 94.82 | 47.42 | 40.47 | 29.92 | Upgrade
|
| Other Operating Expenses | -4.64 | -2.8 | -2.31 | -0.87 | -0.8 | -0.88 | Upgrade
|
| Operating Expenses | 101.23 | 125.71 | 115.64 | 60.51 | 50.94 | 40.92 | Upgrade
|
| Operating Income | -65.49 | -85.98 | -46.46 | 22.13 | -4.86 | -12.58 | Upgrade
|
| Interest Expense | -9.99 | -10.67 | -8.69 | -0.86 | -0.87 | -5.5 | Upgrade
|
| Interest & Investment Income | 4.45 | 4.91 | 0.97 | - | 0.03 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.09 | 1.94 | -7.98 | - | - | -0.97 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.62 | -0.53 | -0.07 | -0.03 | -0.04 | -0.06 | Upgrade
|
| EBT Excluding Unusual Items | -71.75 | -90.34 | -62.21 | 21.25 | -5.74 | -19.01 | Upgrade
|
| Merger & Restructuring Charges | -1.5 | - | -5.1 | -1.2 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.55 | 1.02 | 21.39 | - | - | - | Upgrade
|
| Asset Writedown | -99.22 | -99.21 | -0.05 | -0.17 | -0.83 | -1.88 | Upgrade
|
| Pretax Income | -171.92 | -188.53 | -45.98 | 19.88 | -6.57 | -20.89 | Upgrade
|
| Income Tax Expense | -4.02 | -4.37 | -0.82 | 0.87 | -0.33 | -4.82 | Upgrade
|
| Earnings From Continuing Operations | -167.9 | -184.16 | -45.16 | 19.01 | -6.25 | -16.07 | Upgrade
|
| Minority Interest in Earnings | 25.88 | 26.67 | 6 | - | - | - | Upgrade
|
| Net Income | -142.02 | -157.49 | -39.16 | 19.01 | -6.25 | -16.07 | Upgrade
|
| Net Income to Common | -142.02 | -157.49 | -39.16 | 19.01 | -6.25 | -16.07 | Upgrade
|
| Shares Outstanding (Basic) | 101 | 97 | 95 | 83 | 80 | 73 | Upgrade
|
| Shares Outstanding (Diluted) | 101 | 97 | 95 | 86 | 80 | 73 | Upgrade
|
| Shares Change (YoY) | 4.65% | 1.82% | 10.76% | 7.10% | 9.95% | 5.01% | Upgrade
|
| EPS (Basic) | -1.41 | -1.63 | -0.41 | 0.23 | -0.08 | -0.22 | Upgrade
|
| EPS (Diluted) | -1.41 | -1.63 | -0.41 | 0.22 | -0.08 | -0.22 | Upgrade
|
| Free Cash Flow | -72.09 | -38.35 | -28.91 | 15.99 | -10.24 | -29.28 | Upgrade
|
| Free Cash Flow Per Share | -0.71 | -0.40 | -0.30 | 0.19 | -0.13 | -0.40 | Upgrade
|
| Gross Margin | 36.74% | 44.37% | 49.42% | 57.87% | 52.52% | 44.23% | Upgrade
|
| Operating Margin | -67.32% | -96.03% | -33.19% | 15.50% | -5.54% | -19.64% | Upgrade
|
| Profit Margin | -145.98% | -175.89% | -27.97% | 13.31% | -7.12% | -25.08% | Upgrade
|
| Free Cash Flow Margin | -74.11% | -42.83% | -20.65% | 11.20% | -11.67% | -45.71% | Upgrade
|
| EBITDA | -55.94 | -70.09 | -31.1 | 32.66 | 3.6 | -7.45 | Upgrade
|
| EBITDA Margin | -57.50% | -78.27% | -22.22% | 22.87% | 4.10% | -11.63% | Upgrade
|
| D&A For EBITDA | 9.55 | 15.9 | 15.36 | 10.53 | 8.46 | 5.14 | Upgrade
|
| EBIT | -65.49 | -85.98 | -46.46 | 22.13 | -4.86 | -12.58 | Upgrade
|
| EBIT Margin | -67.32% | -96.03% | -33.19% | 15.50% | -5.54% | -19.64% | Upgrade
|
| Effective Tax Rate | - | - | - | 4.37% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.